TwinStrand beats Guardant Health in patent case, wins $245.2M. GSK's hepatitis B drug bepirovirsen (Hibsago) approved in Japan, under US review. Erasca gets FDA fast-track for pancreatic cancer look-alike.
TwinStrand Biosciences wins patent case: The DNA sequencing company, which spun out of the University of Washington, announced on Monday that …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest
Guardant Health Hit With Royalties Over Duplex Sequencing Tech - Guardant Health (NASDAQ:GH)
US Court to pharma giant Guardant Health: You willfully infringed patents for cancer-testing; asked to pay $245 million to University of Washington
Guardant Bleeds After Losing A Costly Patent Dispute
TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the…
Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a…
A federal judge has finalized a judgment ordering pharma giant Guardant Health to pay more than $245 million to Seattle-based…
Guardant Health stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences.
Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout
GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by…
